Objective: The aim of this study is to confirm the prognostic value of pfetin in gastrointestinal stromal tumor patients. We recently reported the utility of pfetin, a novel prognostic biomarker in gastrointestinal stromal tumor. Gastrointestinal stromal tumor spans a wide spectrum from cases with curable disease to those with fatal tumors due to metastasis and recurrence. There is no biomarker predicting metastasis and/or recurrence of gastrointestinal stromal tumor though imatinib mesylate can improve recurrence-free survival. Methods: Pfetin expression was examined in 40 gastrointestinal stromal tumor patients from the Juntendo University Shizuoka Hospital using immunohistochemistry. Correlations between immunohistochemical findings and clinicopathologic parameters were examined. The pfetin expression results were integrated with the clinicopathologic data in a total of 299 cases including our 40 new gastrointestinal stromal tumor cases and 259 others with previously reported data. Results: Immunohistochemical study demonstrated the disease-free survival rate to be 93.75% for pfetin-positive and 25.0% for pfetin-negative patients among the 40 cases from the Juntendo University Shizuoka Hospital (P ¼ 0.0006). When all 299 cases were included, the disease-free survival rate was 92.44% for pfetin-positive and 60.81% for pfetin-negative patients (P , 0.0001). Both uni-and multivariate analyses revealed that, among the clinicopathologic parameters examined, only pfetin expression was an independent prognostic factor (P , 0.05). Conclusions: These results confirm the possible clinical utility of pfetin as a prognostic biomarker for gastrointestinal stromal tumor. Pfetin appears to be a novel clinically applicable prognostic factor, which may be useful for deciding whether to administer imatinib mesylate or not.
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are rare, but constitute the most common mesenchymal malignancies of the gastrointestinal tract, with an incidence of 15 per 1 000 000 people. The prognosis of GIST is variable, and the proportion of highly malignant or high-risk GIST is 20 -35% of the total (1, 2) . GIST arises from the interstitial cells of Cajal and is characterized by the presence of gain-of-function mutations in c-kit or the platelet-derived growth factor receptor (3) . These mutations result in constitutive activation of signaling pathways, and a small molecule tyrosine kinase inhibitor, namely imatinib mesylate (STI571, Novartis), is reported to be highly effective in the treatment of advanced GIST and in the improvement of recurrence-free survival (4 -6) . Although the benefits of imatinib mesylate are obvious, GIST spans a wide spectrum from curable tumors to those causing death via metastasis and recurrence. Thus, only a limited number of patients may benefit from treatment. In addition, a recent report demonstrated that non-continuous use of imatinib mesylate resulted in tumor progression in most patients (7) . Thus, a prognostic biomarker after surgery would be beneficial for selecting patients most likely to develop recurrence, and who would thus benefit from treatment with imatinib mesylate. Tumor location, risk classification and certain molecular aberrations have been shown to correlate with prognosis and responsiveness to imatinib treatment (8 -12) . However, these biomarkers have not been found to be clinically applicable. Recently, we reported a novel application of pfetin [potassium channel tetramerization domain-containing 12 (KCTD12)] as a prognostic biomarker for GIST using a proteomic approach (13) . Pfetin was originally cloned as a gene, highly expressed in the fetal cochlea and brain (14) . Pfetin belongs to the family of proteins containing the KCTD (14) and its contributions to carcinogenesis and cancer progression have yet to be elucidated. As described in our previous report, immunohistochemical study of pfetin expressions in 210 cases from the National Cancer Center revealed a 5-year disease-free survival rate of 93.9% for pfetin-positive patients and 36.2% for pfetin-negative patients using polyclonal antibody against pfetin (13) . We succeeded in developing a novel monoclonal antibody against pfetin, and thereby confirmed the prognostic value of pfetin in 159 GIST cases from the National Cancer Center and 100 GIST cases from the Niigata University Medical and Dental Hospital. The disease-free survival rate was 93.2 and 94.5% for pfetin-positive patients and 70.0 and 80.7% for pfetin-negative patients in 159 cases from the National Cancer Center and in the 100 cases from the Niigata University Medical and Dental Hospital, respectively (15) . Considering the clinical and genetic heterogeneities of GIST, a further validation study was needed before application of pfetin in the clinical setting.
In this study, we examined the correlations of pfetin expression with clinicopathologic parameters in 40 newly enrolled GIST cases from the Juntendo University Shizuoka Hospital. The annual incidence of GIST estimates 1500 -2000 patients in Japan (1). Thus, 40 cases account for 4 -8% of total number of GIST. We further confirmed the prognostic value of pfetin in 299 GIST cases, including 40 new cases, 159 cases from the National Cancer Center Hospital and 100 cases from the Niigata University Medical and Dental Hospital. Our results indicate that determining pfetin expression can be useful in clinical practice as a prognostic indicator for GIST patients.
PATIENTS AND METHODS

PATIENTS
We examined the primary tumor tissues of 40 GIST patients who underwent surgery at the Juntendo University Shizuoka Hospital during the period from 1995 through 2009. All patients underwent resection with curative intent and were not given adjuvant treatments, including imatinib. Diagnosis was based on the World Health Organization classification system for soft-tissue tumors: tumor size, presence of necrosis, differentiation, mitotic rate, MIB-1 index and presence of epithelioid cells (16) . Risk classification was based on tumor size and the MIB-1 index (17). C-kit expression in all GIST samples was confirmed using immunohistochemical staining (CD117 antibody, DAKO Japan Corp., Tokyo, Japan). clinicopathologic features of the 40 GIST patients are listed in Table 1 and summarized in Table 2 .
We integrated the pfetin expressions in these 40 cases and the other 259 patients from our previous reports: 159 patients underwent surgery at the National Cancer Center between 1974 and 2005 (Supplementary table 1 (15) . In our previous study, we immunohistochemically examined pfetin expressions in the primary tumors of these 259 cases using the same monoclonal antibody as in the present study. The groups of GIST patients are 
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Pfetin as a prognostic biomarker in GIST summarized in Table 3 . The institutional review boards of the National Cancer Center, the Niigata University Medical and Dental Hospital, and the Juntendo University Shizuoka Hospital approved this study. Written informed consent was obtained from all patients examined.
IMMUNOHISTOCHEMISTRY
Pfetin expression was examined immunohistochemically using paraffin-embedded tissues, as described in our previous report (15) . In brief, 4-mm-thick tissue sections were autoclaved in 10 mmol/l citrate buffer ( pH 6.0) at 1218C for 30 min and incubated with the antibody against pfetin (1:1000 dilution).
Immunostaining was carried out according to the streptavidinbiotin peroxidase method using the Strept ABC complex/horseradish peroxidase kit (DAKO). One pathologist (A.Y.) and one clinician (D.K.) reviewed the sections stained with anti-pfetin antibody. Both were blinded to the clinical data (age, sex, anatomic site and outcome). Positively stained cells were defined as those that showed the highest values and were used as positive controls. Cases in which .20% of tumor cells were stained with the anti-pfetin antibody were considered to be Jpn J Clin Oncol 2011;41 (10) pfetin positive, whereas those in which ,20% tumor cells were stained with the anti-pfetin antibody were considered to be pfetin negative, in accordance with our previous report (15) . In most cases, the difference was quite obvious and the two reviewers concurred with the results.
STATISTICAL ANALYSIS
All statistical analyses were carried out using the x 2 test or Fisher's exact test in cross tables to assess the relationships between pfetin expression and clinicopathologic factors. The tumor-specific and disease-free survivals were calculated from the initial resection of the primary tumor until death from tumor-specific causes or until first evidence of metastasis and recurrence, respectively. All time-to-event endpoints were computed by the Kaplan -Meier method (18) . Patients who died of causes unrelated to GIST were censored at the time of death. Potential prognostic factors were identified by univariate analysis using the log-rank test. Independent prognostic factors were evaluated using Cox's proportional hazards regression (19) model with significant variables at the univariate level (P , 0.05). Calculations were carried out using the SPSS software statistical package (SPSS Japan, Inc., Tokyo, Japan).
RESULTS
LOCALIZATION AND EXPRESSION OF PFETIN IN THE PRIMARY GIST
We examined pfetin expressions in the primary tumors of the 40 GIST patients managed at the Juntendo University Shizuoka Hospital, applying our original monoclonal antibody (15) . Immunohistochemistry showed diffuse staining of the membranes and the cytoplasm of tumor cells with the anti-pfetin monoclonal antibody (Fig. 1) . High expression of pfetin was observed in Sample no. 1, obtained from a patient with a good outcome (Fig. 1A and 1B) , while low expression of pfetin was observed in Sample no. 9 from a patient with a poor outcome (Fig. 1C and 1D ). These observations were consistent with those in our previous study (15) .
SURVIVAL ANALYSES OF PFETIN EXPRESSION IN 40 GIST CASES
In these 40 cases, Kaplan -Meier survival analysis revealed pfetin expression to correlate significantly and inversely with recurrence (Fig. 2) . Disease-free survival periods were longer in pfetin-positive than in pfetin-negative cases; the disease-free survival rate was 93.75% (30/32) for pfetinpositive and 25% (2/8) for pfetin-negative cases (P ¼ 0.0006; log-rank test). Uni-and multivariate analyses revealed pfetin expression to be an independent significant predictor of disease-free survival [P ¼ 0.049; relative risk ¼ 0.163; 95% confidence interval (CI): 0.027-0.989; Table 2 ].
META-ANALYSES OF PROGNOSTIC VALUE OF PFETIN EXPRESSION IN MULTIPLE CLINICAL FACILITIES
In a previous report, we demonstrated the possible prognostic value of pfetin in 159 GIST cases from the National Cancer Center and 100 GIST cases from the Niigata University Medical and Dental Hospital, using the same monoclonal antibody as in this study. The all-disease-free survival rates were 90.8 and 94.6% for pfetin-positive patients and 67.5 and 61.5% for pfetin-negative patients in the 159 cases from the National Cancer Center and in the 100 cases from the Niigata University Medical and Dental Hospital, respectively. By combining these data and those from the 40 newly enrolled cases, we obtained pfetin 1198 Pfetin as a prognostic biomarker in GIST expressions and clinicopathologic observations from a total of 299 cases in three hospitals. In these 299 cases, Kaplan -Meier survival analysis revealed pfetin expression to correlate significantly with recurrence and metastasis; the disease-free survival rate was 92.44%, 208/225) for pfetinpositive cases and 60.81% (45/74) for pfetin-negative cases (P , 0.0001, log-rank; Fig. 3A) . Uni-and multivariate analyses of the total 299 cases revealed risk classification and pfetin expression to be significant predictors of disease-free survival (P , 0.001, relative risk ¼ 3.836, 95% CI ¼ 2.126 -6.921; P ¼ 0.002, relative risk ¼ 0.351, 95% CI ¼ 0.181 -0.681; Table 4 ).
We investigated the relationship between the histologically determined risk classification and disease-free survival. Metastasis after surgery was observed in 4 of 159 patients (2.6%) in the low-risk group, 6 of 67 (9.0%) in the intermediate-risk group and 36 of 73 (49.3%) in the high-risk group (Fig. 3B ). There was a significant correlation between the risk classification and postoperative metastasis of GIST (Table 4) .
The disease-free survival rate was significantly higher in the pfetin-positive than in the pfetin-negative group within each risk category. In the low-risk group, the disease-free survival rate was 98.53% for pfetin-positive and 91.30% for pfetin-negative patients (P ¼ 0.0432, log-rank; Fig. 3C ). In the intermediate-risk group, the disease-free survival rate was 96.08% for the pfetin-positive and 75% for the pfetinnegative patients (P ¼ 0.0066, log-rank; Fig. 3D ). In the high-risk group, the disease-free survival rate was 65.79% for the pfetin-positive and 34.29% for pfetin-negative patients (P ¼ 0.0169, log-rank; Fig. 3E ).
DISCUSSION
A biomarker predicting postoperative metastasis would be a useful indicator allowing the optimal therapeutic strategy for GIST to be selected. In a previous study, we demonstrated the prognostic value of pfetin expression in GISTs using a proteomic approach (13) , and later confirmed this in another set of cases (15) . Herein, we further validated our results in 40 newly enrolled GIST cases. We found that pfetin expression correlated significantly with the disease-free (12) and monoclonal antibodies (14) . Note that pfetin expression was observed in the cytoplasm and nucleus. survival of GIST patients, an observation consistent with those in our previous reports. When the previous data from another 259 cases were included, pfetin expression also correlated significantly with the disease-free survival of GIST patients. While the risk classification showed a high correlation with prognosis, clinical outcomes differed significantly according to pfetin expressions in patients in the intermediate-risk group. Thus, determining pfetin expression may be beneficial for intermediate-risk patients, who are more likely to have metastasis and thus should receive imatinib mesylate treatment.
Clinical outcome of the GIST patients depended on the facilities. The disease-free survival rates for pfetin-negative patients in the National Cancer Center, the Niigata University Medical and Dental Hospital, and the Juntendo University Shizuoka Hospital were 67.5, 61.5 and 25.0%, respectively. These differences of disease-free survival rate may be associated with (i) the time of recurrence or Figure 3 . The Kaplan -Meier estimated disease-free survival curves are illustrated for 299 patients based on pfetin expression. Statistically significant differences in disease-free survival periods were observed between the pfetin-positive and -negative cases in the 40 cases (A). The curve is also illustrated for 299 patients based on risk classification group. Statistically significant differences were observed among the each risk group (B). The Kaplan -Meier estimated disease-free survival curves illustrated based on pfetin expression in low-, intermediate-and high-risk groups (C, D and E, respectively).
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Pfetin as a prognostic biomarker in GIST Jpn J Clin Oncol 2011;41 (10) 1201 examined. Because of the clinical and genetic heterogeneity of GIST, our data sets were important to evaluate the novel biomarker before using clinical application. We anticipate that our study results will lead to a novel clinically applicable prognostic marker allowing routine diagnosis and evaluation of the malignancy risk of GIST. Immunohistochemical examination of pfetin expression and the development of molecular targeting agents will provide novel therapeutic strategies to prevent recurrence of GIST. Larger scale validation studies and a functional investigation of pfetin will be our next challenges.
